scholarly journals Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer

BJUI Compass ◽  
2021 ◽  
Author(s):  
Yuki Miura ◽  
Shingo Hatakeyama ◽  
Toshikazu Tanaka ◽  
Naoki Fujita ◽  
Hirotaka Horiguchi ◽  
...  
Keyword(s):  
Urothelial Cancer ◽  
Locally Advanced ◽  
Prognostic Impact ◽  
Adjuvant Immunotherapy ◽  
Advanced Urothelial Cancer

Neoadjuvant Chemotherapy for Locally Advanced Urothelial Cancer of the Upper Urinary Tract

1995 ◽  
Vol 55 (2) ◽  
pp. 74-77 ◽  
Author(s):  
M. Igawa ◽  
S. Urakami ◽  
H. Shiina ◽  
H. Kishi ◽  
Y. Himeno ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Neoadjuvant Chemotherapy ◽  
Urothelial Cancer ◽  
Locally Advanced ◽  
Upper Urinary Tract ◽  
Advanced Urothelial Cancer

scholarly journals Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy

2020 ◽  
Vol 21 (5) ◽  
pp. 1850 ◽  
Author(s):  
Seung-Woo Baek ◽  
In-Hwan Jang ◽  
Seon-Kyu Kim ◽  
Jong-Kil Nam ◽  
Sun-Hee Leem ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Survival Analysis ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Urothelial Cancer ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Prognostic Impact ◽  
T Effector Cells ◽  
Advanced Urothelial Cancer

Recent investigations reported that some subtypes from the Lund or The Cancer Genome Atlas (TCGA) classifications were most responsive to PD-L1 inhibitor treatment. However, the association between previously reported subtypes and immune checkpoint inhibitor (ICI) therapy responsiveness has been insufficiently explored. Despite these contributions, the ability to predict the clinical applicability of immune checkpoint inhibitor therapy in patients remains a major challenge. Here, we aimed to re-classify distinct subtypes focusing on ICI responsiveness using gene expression profiling in the IMvigor 210 cohort (n = 298). Based on the hierarchical clustering analysis, we divided advanced urothelial cancer patients into three subgroups. To confirm a prognostic impact, we performed survival analysis and estimated the prognostic value in the IMvigor 210 and TCGA cohort. The activation of CD8+ T effector cells was common for patients of classes 2 and 3 in the TCGA and IMvigor 210 cohort. Survival analysis showed that patients of class 3 in the TCGA cohort had a poor prognosis, while patients of class 3 showed considerably prolonged survival in the IMvigor 210 cohort. One of the distinct characteristics of patients in class 3 is the inactivation of the TGFβ and YAP/TAZ pathways and activation of the cell cycle and DNA replication and DNA damage (DDR). Based on our identified transcriptional patterns and the clinical outcomes of advanced urothelial cancer patients, we constructed a schematic summary. When comparing clinical and transcriptome data, patients with downregulation of the TGFβ and YAP/TAZ pathways and upregulation of the cell cycle and DDR may be more responsive to ICI therapy.

Impact of dose density of adjuvant chemotherapy for locally advanced urothelial cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4567-4567
Author(s):  
T. B. Dorff ◽  
J. Cai ◽  
G. Miranda ◽  
E. C. Skinner ◽  
A. Schuckman ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Urothelial Cancer ◽  
Locally Advanced ◽  
Advanced Urothelial Cancer

Use of multidrug-resistance gene (MDR1) expression levels to predict outcome to adjuvant cisplatin/gemcitabine based chemotherapy in patients with with locally advanced urothelial cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22081-e22081
Author(s):  
T. Gauler ◽  
A. C. Hoffman ◽  
P. Wild ◽  
C. Leicht ◽  
S. Bertz ◽  
...  
Keyword(s):  
Gene Expression ◽  
Urothelial Cancer ◽  
Locally Advanced ◽  
Mdr1 Gene ◽  
Mrna Levels ◽  
Expression Levels ◽  
Mdr1 Gene Expression ◽  
Mdr1 Expression ◽  
Advanced Urothelial Cancer ◽  
Gene Expression Levels

e22081 Background: The human MDR1 gene encodes an integral membrane protein, P glycoprotein (Pgp), whose function is the energy dependent export of substances from the inside of cells, and from membranes, to the outside. MDR1 mRNA levels have been shown to influence metabolism of cancer drugs. We tested whether MDR1 gene expression is associated with outcome in patients with locally advanced bladder cancer. Methods: 43 formalin fixed paraffin embedded (FFPE) tumor samples from patients with locally advanced and/or lymph node-positive bladder cancer undergoing treatment with cisplatin/gemcitabine were analyzed.FFPE tissues were dissected using laser-captured microdissection and analyzed for MDR1 expression using a quantitative real- time RT-PCR method. Gene expression values (relative mRNA levels) are expressed as ratios between the target gene and internal reference gene (beta-actin). Results: MDR1 was significantly correlated to overall survival. We included tumor stage (pT), lymph node status (pN) and the blood vessel invasion along with the measured gene expression in a stepwise multivariate Cox proportional hazards regression model. The overall model fit had a significance level of p=0.04 (<0.05). The relative risk for shorter survival in patients with High MDR1 expression was 1.9. Conclusions: These results suggest that MDR1 gene expression levels predict response and overall survival in patients with locally advanced urothelial cancer. MDR1 gene expression levels may allow the selection of patients who benefit likely from adjuvant cisplatin/gemcitabine based chemotherapy. Further studies are warranted to study this association. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document